• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Illumina Stock Misses Revenue But Lifts Full Year Outlook

    Simply Wall St·11/01/2026 00:38:49
    语音播报
    • Illumina reported past third quarter 2026 results with US$1.129b in revenue and US$220m in net income, then raised full year sales guidance to a range of US$4.64b to US$4.66b alongside higher EPS expectations.
    • The firm paired this financial update with new AI driven BioInsight Platform capabilities and strong NovaSeq X adoption, underscoring a shift toward higher margin software, data and clinical consumables alongside its sequencing hardware base.
    • We will now look at how Illumina's raised full year guidance reshapes the existing investment narrative built around clinical sequencing.
    Seize this pullback in Illumina to reassess your exposure to genomics and AI driven sequencing by comparing it with 34 healthcare AI stocks.

    Illumina Investment Narrative Recap

    To own Illumina, you need to believe clinical sequencing, consumables and data products can support steady earnings while the transition to NovaSeq X and AI tools matures. The Q3 2026 report, with US$1.129b in revenue and US$220m in net income, plus raised full year guidance, points to an operating setup that is currently holding together.

    The key near term swing factor is whether clinical consumables and NovaSeq X volume stay strong enough to offset softer research demand and any China related friction. The biggest risk is that growth expectations remain high while organic revenue, still described at just over 4%, does not keep pace. This could leave Illumina exposed to further sentiment shocks.

    Among recent updates, the BioInsight Platform and new AI powered capabilities look most relevant to Illumina's current story. Workflow Orchestrator, DRAGEN Ultra and Learning Cohorts all focus on turning sequencing runs into higher value analytics, which ties directly into the market narrative around genomics and AI enabled biology as a long term earnings engine.

    For you as an investor, the operational question is whether Illumina can scale BioInsight from early access tools into material, recurring software and data revenue that complements NovaSeq X consumables. The main execution risks sit around adoption, pricing, and competition from other AI centric genomic platforms, especially while the stock is already priced for meaningful growth and margin improvement.

    What The Current Illumina Forecasts Assume

    Analyst models around Illumina are explicit about what needs to happen over the next few years. Consensus assumes revenue expands by 7.1% a year, profit margins lift from 18.3% today to 20.7% in three years, and earnings move from US$824.0m now to US$1.1b by 2029, with some forecasts as high as US$1.3b. To line up with these projections, you would also need to be comfortable with the stock trading on a P/E of 40.1x those 2029 earnings, compared with 51.2x today and a US Life Sciences industry multiple of 38.1x, as well as a modest 1.18% yearly decline in the share count.

    Illumina's narrative projects US$5.5b revenue and US$1.1b earnings by 2029. This rests on 7.1% yearly revenue growth and an earnings increase of about US$276m from US$824.0m today.

    Uncover why Illumina's fair value indicates a 5% potential upside to its current price that could narrow quickly.

    NasdaqGS:ILMN 1-Year Stock Price Chart
    NasdaqGS:ILMN 1-Year Stock Price Chart

    Exploring Other Perspectives

    The biggest swing factor in the bearish narrative is competition. While the baseline view leans on Illumina’s BioInsight and NovaSeq X momentum, the lowest analysts were focused on rivals like Roche’s Axelios system potentially pressuring pricing. They were working off earlier forecasts of about US$5.3b revenue and US$1.1b earnings by 2029, which is a much tougher stance. You should expect those opinions to evolve after this new guidance and Q3 update. Treat them as starting points and explore a range of views before deciding how this pullback fits your own thesis.

    Explore 3 other Illumina fair value estimates, including one that suggests it could be worth just $234.92.

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more Illumina sized investment ideas?

    If the Illumina story has you rethinking your exposure to healthcare and growth, it can help to line it up against a wider watchlist built from clear, rules based filters on balance sheets, income streams and pricing power.